Status:
COMPLETED
Dalbavancin in Real Clinical Practice in Spain
Lead Sponsor:
Angelini Farmacéutica
Collaborating Sponsors:
Effice Servicios Para la Investigacion S.L.
Conditions:
Skin Diseases, Bacterial
Skin Diseases, Infectious
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to describe the real clinical use of Dalbavancin in Spain between January 2018 and December 2019.
Detailed Description
Dalbavancin is a new lipoglycopeptide approved for the treatment of ABSSSIs (Acute Bacterial Skin and Skin-Structure Infections) with activity against Gram-positive pathogens, including MRSA. Dalbavan...
Eligibility Criteria
Inclusion
- Adult man and woman (≥ 18 years) at the time of receiving dalbavancin
- Patients receiving at least one dose of dalbavancin between 1st January 2018 and 31st December 2019
- Patients with medical follow-up information registered in clinical records for about 90 days after completing the treatment
- Written informed consent requested according to local regulation, IEC and protocol requirements
Exclusion
- 1\. Patient enrolled in a clinical trial in which treatment with dalbavancin is managed through a protocol
Key Trial Info
Start Date :
July 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 21 2021
Estimated Enrollment :
187 Patients enrolled
Trial Details
Trial ID
NCT04485676
Start Date
July 15 2020
End Date
February 21 2021
Last Update
July 22 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario A Coruña
A Coruña, Spain, 15006
2
Hospital Universitari Vall d'Hebrón
Barcelona, Spain, 08035
3
Hospital Clínic Barcelona
Barcelona, Spain, 08036
4
Hospital Universitario Virgen de las Nieves
Granada, Spain, 18014